Results of the Pivotal BELIEF Phase II Trial of Single-Agent Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma


Results of the Pivotal BELIEF Phase II Trial of Single-Agent Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
Slides from presentations at ASCO 2013 and ICML 2013 and transcribed comments from a recent interview with Owen A O’Connor, MD, PhD (8/20/13)

O’Connor OA et al. Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELIEF trial. Proc ASCO 2013;Abstract 8507.

Horwitz S et al. Belinostat in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL) subtype angioimmunoblastic T-cell lymphoma (AITL): Results from the pivotal BELIEF trial. Proc ICML 2013;Abstract 153.

Dr O’Connor is Professor of Medicine and Developmental Therapeutics and Director of the Center for Lymphoid Malignancies at Columbia University Medical Center in New York, New York.